Evidence map›Paper›PMID 40966286›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Divergent sustainability profiles of molnupiravir synthesis routes are governed by solvent use and process design.

Zhengyun Chen, Justin Z Lian, Haozhou Huang, Hengyi Zhu, Lynda Thubelihle Kanye, Mateng Chen, Zhihao Zhang, Boxin Liu, Jiawei Zhang, Ajaz Ahmed and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhengyun Chen *Department of Pharmaceutical Engineering, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Justin Z Lian *Department of Industrial Ecology, Institute of Environmental Science-Industrial Ecology, Leiden University, Leiden 2333 CC, The Netherlands.ORCID 0009-0005-0254-4516
Haozhou HuangCourant Institute of Mathematical Sciences, New York University, New York, NY 10012.
Hengyi ZhuSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Lynda Thubelihle KanyeDepartment of Pharmaceutical Engineering, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Mateng ChenSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Zhihao ZhangSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Boxin LiuSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Jiawei ZhangDepartment of Aeronautics, Imperial College London, London SW7 2AZ, United Kingdom.ORCID 0000-0003-3534-9299
Ajaz AhmedDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095-1569.
Valerio BarbarossaDepartment of Industrial Ecology, Institute of Environmental Science-Industrial Ecology, Leiden University, Leiden 2333 CC, The Netherlands.ORCID 0000-0002-0519-6968
Stefano CucurachiDepartment of Industrial Ecology, Institute of Environmental Science-Industrial Ecology, Leiden University, Leiden 2333 CC, The Netherlands.
Bin DongDepartment of Pharmaceutical Engineering, China Pharmaceutical University, Nanjing 210009, People's Republic of China.

Funding

LIFE-GREENAPI 101114152National innovation and Enterpreneurship training program for undergraduate 345
6 · The paper itself

Abstract

This study presents a comparative cradle-to-gate environmental and economic evaluation of nine synthetic routes for Molnupiravir (EIDD-2801), a broad-spectrum antiviral drug. Integrating Life Cycle Assessment (LCA) with Life Cycle Costing (LCC), we quantified the environmental impacts alongside capital and operational costs, net present costs, and break-even prices of each route. The results reveal significant variation across the schemes, with

Indexed as

antiviral drugslife cycle assessmentlife cycle cost (LCC)Molnupiravir (EIDD-2801)process optimization

Identifiers

PMID40966286
PMCPMC12478064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.